We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




European Partnership to Promote Development of Anticancer Cell Therapy Products

By LabMedica International staff writers
Posted on 19 Jul 2015
Print article
A leading European contract manufacturing organization is teaming up with a start-up biotech company to promote the clinical development of two unique anticancer cell therapy products.

PharmaCell BV (Maastricht, the Netherlands) is a leading European-based contract manufacturing organization in the area of cell therapy and regenerative medicine. PharmaCell has experience in supporting Phase I through Phase III clinical trials and early commercial manufacturing of cell therapy products.

PharmaCell is located in the center of Europe and operates two state-of-the-art GMP (good manufacturing practices)-licensed facilities with combined area of more than 4,500 square meters for growth of human cells and tissues.

CiMaas (Maastricht, the Netherlands) is a biotech startup spin-off of Maastricht University (the Netherlands) focused on the development of immune cell therapy for cancer patients. The company’s lead products are a dendritic cell vaccine that is ready to be validated and tested in clinical trials and natural killer (NK) cells obtained from healthy donors that have already proven in rodent studies to demonstrate great antitumor activity.

PharamaCell and CiMaas have agreed to collaborate on the clinical development of CiMaas’ products. Under the agreement, PharmaCell will provide consulting services for the writing of GMP-compliant documents for the purpose of translating CiMaas' cell therapy processes into GMP compatible clinical products. Options have been taken on a full technology transfer trajectory to be started and executed at a later date. A continuation option on a Phase I and possibly a Phase II clinical trial is also part of the agreement.

Dr. Wilfred Germeraad, CSO of CiMaas, said, “It is a wonderful opportunity to work together and it will immediately speed-up our work in translating the lab procedures into clinical products ready to be tested in patients with cancer.”

Alexander Vos, CEO of PharmaCell BV, said, “The CiMaas team has shown to be successful in bringing their technology to the point of preparing the initiation of clinical studies. We are excited to support them to make their production process GMP-compliant and help clear the path to bring their innovative therapies to benefit patients.”

Related Links:

PharmaCell BV
CiMaas
Maastricht University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.